Lebrikizumab Dosed Every 8 Weeks as Maintenance Provides Long-Lasting Response in Patients with Moderate-to-Severe Atopic Dermatitis. (2025). SKIN The Journal of Cutaneous Medicine, 9(6), s601. https://doi.org/10.25251/14pn6v71